PMID- 26801082
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20171211
IS  - 1460-2091 (Electronic)
IS  - 0305-7453 (Linking)
VI  - 71
IP  - 4
DP  - 2016 Apr
TI  - Pristinamycin in the treatment of MSSA bone and joint infection.
PG  - 1063-70
LID - 10.1093/jac/dkv457 [doi]
AB  - OBJECTIVES: The aim of this study was to evaluate pristinamycin in the treatment 
      of MSSA bone and joint infection (BJI). PATIENTS AND METHODS: A retrospective, 
      single-centre cohort study (2001-11) investigated outcome in adults receiving 
      pristinamycin for MSSA BJI and pristinamycin-related adverse events (AEs). 
      RESULTS: One hundred and two MSSA BJIs were assessed in 98 patients [chronic 
      infection, 33.3%; and orthopaedic device-related infection (ODI), 67.6%]. Surgery 
      was performed in 77.5% of total cases, and in all but three ODIs, associated with 
      antibiotic therapy of a median total duration of 29.2 weeks. Pristinamycin was 
      prescribed as a part of the initial intensive treatment phase (29.4%) and/or 
      included in final maintenance therapy (83.3%) at a dose of 47.6 (45.5-52.6) 
      mg/kg/day for 9.3 (1.4-20.4) weeks. AEs occurred in 13.3% of patients, consisting 
      of gastrointestinal disorder (76.9%) or allergic reaction (23.1%), leading to 
      treatment interruption in 11 cases. AEs were related to daily dose (OR, 2.733 for 
      each 10 additional mg/kg/day; P = 0.049). After a follow-up of 76.4 (29.6-146.9) 
      weeks, the failure rate was 34.3%, associated with ODI (OR, 4.421; P = 0.006), 
      particularly when the implant was retained (OR, 4.217; P = 0.007). In most 
      patients, the pristinamycin companion drug was a fluoroquinolone (68.7%) or 
      rifampicin (21.7%), without difference regarding outcome. CONCLUSIONS: 
      Pristinamycin is an effective, well-tolerated alternative therapeutic option in 
      MSSA BJI, on condition that a daily dosage of 50 mg/kg is respected.
CI  - (c) The Author 2016. Published by Oxford University Press on behalf of the British 
      Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Valour, Florent
AU  - Valour F
AD  - Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la 
      Croix-Rousse, 69004 Lyon, France French Regional Reference Centre for Bone and 
      Joint Infection, Hospices Civils de Lyon, Lyon, France International Centre for 
      Research in Infectiology, INSERM U1111, Claude Bernard Lyon 1 University, Lyon, 
      France florent.valour@chu-lyon.fr.
FAU - Boibieux, Andre
AU  - Boibieux A
AD  - Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la 
      Croix-Rousse, 69004 Lyon, France French Regional Reference Centre for Bone and 
      Joint Infection, Hospices Civils de Lyon, Lyon, France.
FAU - Karsenty, Judith
AU  - Karsenty J
AD  - Department of Infectious Diseases, Chalon-sur-Saone Hospital, Chalon-sur-Saone, 
      France.
FAU - Vallat, Marie-Paule
AU  - Vallat MP
AD  - Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la 
      Croix-Rousse, 69004 Lyon, France French Regional Reference Centre for Bone and 
      Joint Infection, Hospices Civils de Lyon, Lyon, France.
FAU - Braun, Evelyne
AU  - Braun E
AD  - Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la 
      Croix-Rousse, 69004 Lyon, France French Regional Reference Centre for Bone and 
      Joint Infection, Hospices Civils de Lyon, Lyon, France.
FAU - Perpoint, Thomas
AU  - Perpoint T
AD  - Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la 
      Croix-Rousse, 69004 Lyon, France French Regional Reference Centre for Bone and 
      Joint Infection, Hospices Civils de Lyon, Lyon, France.
FAU - Biron, Francois
AU  - Biron F
AD  - Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la 
      Croix-Rousse, 69004 Lyon, France French Regional Reference Centre for Bone and 
      Joint Infection, Hospices Civils de Lyon, Lyon, France.
FAU - Laurent, Frederic
AU  - Laurent F
AD  - French Regional Reference Centre for Bone and Joint Infection, Hospices Civils de 
      Lyon, Lyon, France International Centre for Research in Infectiology, INSERM 
      U1111, Claude Bernard Lyon 1 University, Lyon, France Laboratory of Bacteriology, 
      French National Reference Centre for Staphylococci, Hospices Civils de Lyon, 
      Lyon, France.
FAU - Lustig, Sebastien
AU  - Lustig S
AD  - French Regional Reference Centre for Bone and Joint Infection, Hospices Civils de 
      Lyon, Lyon, France International Centre for Research in Infectiology, INSERM 
      U1111, Claude Bernard Lyon 1 University, Lyon, France Orthopaedic Surgery Unit, 
      Hospices Civils de Lyon, Lyon, France.
FAU - Chidiac, Christian
AU  - Chidiac C
AD  - Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la 
      Croix-Rousse, 69004 Lyon, France French Regional Reference Centre for Bone and 
      Joint Infection, Hospices Civils de Lyon, Lyon, France International Centre for 
      Research in Infectiology, INSERM U1111, Claude Bernard Lyon 1 University, Lyon, 
      France.
FAU - Ferry, Tristan
AU  - Ferry T
AD  - Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la 
      Croix-Rousse, 69004 Lyon, France French Regional Reference Centre for Bone and 
      Joint Infection, Hospices Civils de Lyon, Lyon, France International Centre for 
      Research in Infectiology, INSERM U1111, Claude Bernard Lyon 1 University, Lyon, 
      France.
CN  - Lyon Bone and Joint Infection Study Group
LA  - eng
PT  - Journal Article
DEP - 20160121
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Pristinamycin)
SB  - IM
CIN - J Antimicrob Chemother. 2016 Nov;71(11):3317. PMID: 27365185
CIN - J Antimicrob Chemother. 2016 Nov;71(11):3318. PMID: 27585967
MH  - Aged
MH  - Anti-Bacterial Agents/pharmacology/*therapeutic use
MH  - Arthritis, Infectious/*drug therapy/*microbiology/mortality
MH  - Bone Diseases, Infectious/*drug therapy/*microbiology/mortality
MH  - Cohort Studies
MH  - Combined Modality Therapy
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Methicillin-Resistant Staphylococcus aureus/*drug effects
MH  - Middle Aged
MH  - Pristinamycin/pharmacology/*therapeutic use
MH  - Staphylococcal Infections/*drug therapy/microbiology/mortality
MH  - Treatment Outcome
FIR - Ader, Florence
IR  - Ader F
FIR - Biron, Francois
IR  - Biron F
FIR - Boibieux, Andre
IR  - Boibieux A
FIR - Braun, Evelyne
IR  - Braun E
FIR - Chidiac, Christian
IR  - Chidiac C
FIR - Daoud, Fatiha
IR  - Daoud F
FIR - Ferry, Tristan
IR  - Ferry T
FIR - Gillet, Yves
IR  - Gillet Y
FIR - Hees, Laure
IR  - Hees L
FIR - Lippmann, Johanna
IR  - Lippmann J
FIR - Miailhes, Patrick
IR  - Miailhes P
FIR - Perpoint, Thomas
IR  - Perpoint T
FIR - Roux, Sandrine
IR  - Roux S
FIR - Saison, Julien
IR  - Saison J
FIR - Vallat, Marie-Paule
IR  - Vallat MP
FIR - Valour, Florent
IR  - Valour F
FIR - Barrey, Cedric
IR  - Barrey C
FIR - Berard, Jean-Baptiste
IR  - Berard JB
FIR - Boucher, Fabien
IR  - Boucher F
FIR - Breton, Pierre
IR  - Breton P
FIR - Cantin, Olivier
IR  - Cantin O
FIR - Dalat, Frederic
IR  - Dalat F
FIR - Desmarchelier, Romain
IR  - Desmarchelier R
FIR - Fessy, Michel-Henry
IR  - Fessy MH
FIR - Jacquesson, Timothee
IR  - Jacquesson T
FIR - Jouanneau, Emmanuel
IR  - Jouanneau E
FIR - Lustig, Sebastien
IR  - Lustig S
FIR - Mojallal, Ali
IR  - Mojallal A
FIR - Neyret, Philippe
IR  - Neyret P
FIR - Peltier, Adrien
IR  - Peltier A
FIR - Reynaud, Olivier
IR  - Reynaud O
FIR - Shipkov, Hristo
IR  - Shipkov H
FIR - Signorelli, Francesco
IR  - Signorelli F
FIR - Vermersch, Thibault
IR  - Vermersch T
FIR - Viste, Anthony
IR  - Viste A
FIR - Dupieux, Celine
IR  - Dupieux C
FIR - Laurent, Frederic
IR  - Laurent F
FIR - Rasigade, Jean-Philippe
IR  - Rasigade JP
FIR - Vandenesch, Francois
IR  - Vandenesch F
FIR - Giammarile, Francesco
IR  - Giammarile F
FIR - Janier, Marc
IR  - Janier M
FIR - Morelec, Isabelle
IR  - Morelec I
FIR - Gagnieu, Marie-Claude
IR  - Gagnieu MC
FIR - Goutelle, Sylvain
IR  - Goutelle S
FIR - Tod, Michel
IR  - Tod M
FIR - Mabrut, Eugenie
IR  - Mabrut E
EDAT- 2016/01/24 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/01/24 06:00
PHST- 2015/10/10 00:00 [received]
PHST- 2015/12/02 00:00 [accepted]
PHST- 2016/01/24 06:00 [entrez]
PHST- 2016/01/24 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - dkv457 [pii]
AID - 10.1093/jac/dkv457 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2016 Apr;71(4):1063-70. doi: 10.1093/jac/dkv457. Epub 
      2016 Jan 21.